Pharma

Your Article Summary

See Latest Articles

Active Biotechs rights issue substantially oversubscribed
Active Biotech, 06/16/09

Active Biotech's rights issue of approximately 256 million SEK, with pre-emptive rights for the company's shareholders, has been completed. A count has shown that the issue is oversubscribed by 71 percent; 99.4 percent of the shares offered were subscribed for with the support of subscription rights.

Today in Biotechnology...keeping you current

Receive free subspecialty "5-minute updates" via email

Sanofi-aventis and U.S Biotechnology company Alopexx enter into a collaboration agreement for a novel human monoclonal antibody targeting infectious diseases
Sanofi-aventis, 12/11/09

Quality by Design for Biotechnology Products—Part 2
BioPharm, 12/09/09

Amylin Pharmaceuticals to Present at the 2009 Deutsche Bank Biotech Boston Confab
Amylin Pharmaceuticals, 12/09/09

 See all of Biotechnology